Orthocell Limited (ASX:OCC)
0.5650
-0.0350 (-5.83%)
Oct 22, 2026, 10:39 AM AEDT
Orthocell Revenue
In the fiscal year ending June 30, 2026, Orthocell had annual revenue of 11.41M AUD with 45.37% growth. Orthocell had revenue of 5.99M in the half year ending June 30, 2026, with 53.19% growth. That makes Orthocell the 38,269th largest company in the world by revenue and 702nd in Australia.
Revenue
11.41M
Revenue Growth
+45.37%
P/S Ratio
14.33
Revenue / Employee
n/a
Employees
n/a
Market Cap
153.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 11.41M | 3.56M | 45.37% |
| Jun 30, 2025 | 7.85M | 2.53M | 47.62% |
| Jun 30, 2024 | 5.32M | 1.07M | 25.27% |
| Jun 30, 2023 | 4.24M | 2.71M | 177.01% |
| Jun 30, 2022 | 1.53M | 513.76K | 50.47% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BLS Pharmaceuticals | 73.91M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
| Recce Pharmaceuticals | 9.47M |
| Dimerix | 6.35M |
| Tetratherix | 3.86M |
| Racura Oncology | 2.81M |
| Nyrada | 2.01M |
Orthocell News
- 4 minutes ago - Orthocell Earnings release: Q1 2027 - Filings
- 4 minutes ago - Orthocell Slides: Q1 2027 - Filings
- 7 weeks ago - Orthocell Annual report: H2 2026 - Filings
- 3 months ago - Orthocell Earnings release: Q4 2026 - Filings
- 3 months ago - Orthocell Slides: Q4 2026 - Filings
- 6 months ago - Orthocell Earnings release: Q3 2026 - Filings
- 6 months ago - Orthocell Slides: Q3 2026 - Filings
- 6 months ago - Orthocell Gets Approval To Sell Remplir To The U.S. Department Of Defence Hospital Network - Nasdaq